Carcinotech

A recent study by the National Cancer Institute (NCI) highlights a promising personalised immunotherapy approach for solid tumours. By sequencing patient’s tumours and identifying mutations, researchers were able to tailor treatments that enhance the immune system’s ability to target and destroy cancer cells. Genetically engineered T-cells showed significant tumour shrinkage in some patients. This new strategy overcomes key challenges in cellular immunotherapy, including scaling T-cell production and boosting their ability to multiply after infusion. While still in early stages, this approach holds great potential for more effective cancer treatments. #Immunotherapy #Tcells #CancerResearch

We’re back and we're bioprinting 💪! It’s a full house this week as our team returns from their well-earned Christmas break. As we settle back into our routine, we’re excited to kick off 2025 with renewed energy and focus on transforming cancer research. Also, special shoutout to our amazing scientific team for their efforts in the lab over the festive period ensuring the seamless continuation of our client projects. Hoping everyone had a happy holidays and enjoys a productive week ahead! #BackToWork #LabLife #3DBioprintedTumours

🎉 Wrapping up an incredible 2024 🎉 As the year draws to a close, we’re reflecting on 2024—a year of growth, innovation, and achievements for our team. Here are some of the highlights that made this year stand out: ✨ Team Growth: We doubled our headcount, welcoming new talent who are driving our mission forward. 🌐 Expanded Modalities: We broadened our support for new modalities, advancing the scope of our cancer models. 📢 Sharing Our Work: We had opportunities to present our research at both the European Association for Cancer Research (EACR) Congress and ESMO - European Society for Medical Oncology’s Immuno-Oncology Congress. 🏆 Meaningful Acknowledgements: • Our CEO, Ishani Malhotra, was named "Woman Entrepreneur of the Year" at Cancer Research Horizons’ Innovation & Entrepreneurship Awards. • We won "Lab of the Year" at the Lab Innovations - Lab Awards 2024. • Our Imaging Scientist, Michaela Macdonald, was announced as the June winner of Cancer Research UK (CRUK) #ResearchIsBeautiful campaign for an image of one of Carcinotech’s 3D-bioprinted tumours. None of this would have been possible without our incredible team, and we thank them for all their hard work. We’re also deeply grateful to our board members and investors for their support. We are gearing up for an even better 2025 and have something exciting to share early in the new year! 👀 #YearWrapped #HappyNewYear

🎉 Our team keeps growing! Welcome, Anna Whyte! 🎉 Anna holds an integrated master’s degree in Molecular and Cellular Biology from the University of Glasgow, where her honours project explored the role of cancer-associated fibroblasts in the breast cancer tumour microenvironment. She also gained invaluable expertise in cell culture, working with embryonic stem cells and 3D organoid models during her placement at the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin. Anna’s combined skill set and expertise will play a pivotal role in advancing our innovative cancer models. We’re thrilled to have her on board! Welcome to the team, Anna! 🙌

A recent study by Mayo Clinic highlights a groundbreaking treatment for glioblastoma, the most aggressive brain cancer, especially in patients over 65. Using short-course hypofractionated proton beam therapy with advanced imaging, the approach precisely targets the most aggressive tumour regions. Results show 56% of participants survived beyond 12 months, with a median survival of 13.1 months—rising to 22 months for patients with favourable tumour genetics. This significantly outperforms prior average survival rates of six to nine months. Completed in one to two weeks (vs. the usual three to six), the treatment was well-tolerated, extending survival while protecting healthy brain tissue. These findings bring new hope for improving outcomes in older glioblastoma patients. Watch this video for more information on the study: https://lnkd.in/eYdXMXBA #Oncology #CancerResearch #Glioblastoma

We are welcoming another new member to the team this week. Welcome  Laura Nixon! Laura earned an Honours degree in Biological Sciences with a specialisation in Immunology from The University of Edinburgh, developing a strong foundation in immune system function and molecular biology. Laura began her career at Concept Life Sciences in Edinburgh as an immunologist, conducting advanced cancer drug screening assays, including T-cell exhaustion, macrophage differentiation, and MDSC suppression, with cytokine analysis and flow cytometry. She later transitioned to their neuroscience department where she focused on iPSC culture and maintenance. With expertise spanning immunology, histology, and cell culture, Laura is dedicated to driving innovation in therapeutic development and will be responsible for maintaining Carcinoteh’s innovative tumour models and supporting our assay development. Great to have you onboard Laura 🤩

Thank you to ESMO - European Society for Medical Oncology for hosting us at this year’s Immuno-Oncology Congress. The event was an incredible opportunity to connect with global leaders and explore the latest advancements shaping the future of immuno-oncology. We were thrilled to present our research on 3D-bioprinted tumours as an innovative tool for immunotherapeutic testing. Stay tuned in the new year when our poster will be available for download—we’re excited to share more with you! #ESMOImmunoOncology2024 #CancerResearch #ImmunoOncology

We are delighted to welcome Yaiza R. to Carcinotech this week! Yaiza joins our team with a proven track record of excellence in financial operations, honed as a Finance Assistant at a growing utility startup in Scotland. In this role, she supported the company’s financial processes during a period of significant expansion. Her contributions included assisting with financial reporting, ensuring accuracy in budget management, and collaborating with the wider team. With her hands-on experience in navigating the challenges of a scaling organisation, we are excited to have Yaiza bring her skillset to our team. We are thrilled to have you joining us! 🌟

Attending ESMO Immuno-Oncology Congress 2024 this week?   Make sure to visit the Foyer Mezzanine to explore our poster, “Patient-Derived 3D-Bioprinted Tumours: A Pioneering Tool for Immunotherapeutic Testing.” On Thursday, during the poster display session, our Scientific Manager, Kamila Pawlicka, will be on hand to answer your questions, and provide valuable insights into the application of Carcino3D™ bioprinted tumours in advancing immunotherapeutic testing. We look forward to seeing you there! #ESMOImmunoOncology2024 #CancerResearch #ImmunoOncology

🎄✨ Team Christmas Night Out! ✨🎄 Last night was a fantastic opportunity to stop, reflect, and celebrate our achievements this year. Thank you to all our staff for their unwavering commitment! As we head into the final stretch of 2024, let’s continue the hard work and prepare ourselves for an even better 2025. #HolidayCheers 🥂